DOCSLIB.ORG

Top Ten Drug Interactions That Limit Efficacy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Top Ten Drug Interactions That Limit Efficacy Doing More by Prescribing Less; Top Ten Drug Interactions that Limit Efficacy Paul Zarkowski, MD Clinical Assistant Professor Harborview Medical Center University of Washington Psychiatrist, Sound Seattle, Washington Disclosure • The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational use(s) of drugs, products, and/or devices (any use not approved by the US Food and Drug Administration). – Dr. Zarkowski will be discussing off-label use of prescription medications in the presentation and will identify those issues. • Applicable CME staff have no relationships to disclose relating to the subject matter of this activity. • This activity has been independently reviewed for balance. Polypharmacy • Increasing incidence of ≥ 2 concurrent prescriptions for – Antidepressants – Antipsychotics – Sedative-hypnotics – Antidepressant-antipsychotic combinations – But not other combinations • Rare RPCDB studies of combinations • Uncertain gains for quality of care and clinical outcomes RPCDB = randomized placebo-controlled double-blind. Mojtabai R, et al. Arch Gen Psychiatry. 2010;67(1):26-36. 3 Types of Evidence • Opposing clinical indications and side FDA Indications, Off-Label Uses, and effects suggest an interaction limiting Side Effects efficacy • Underlying mechanism of action suggests an antagonistic interaction at receptors critical for efficacy • Clinical studies with simultaneous administration of medications confirm decreased efficacy – Humans – Rats – Mice Example of Study Exclusion Pramipexole and Antipsychotic Medication Meets First 2 Criteria But RPCDB Supports Combination • Pramipexole caused psychosis in • Augmenting antipsychotic medications with patients treated for RLS pramipexole to 4.25 mg (0.38 mg) – 24 participants (SC or SA) over 12 • Pramipexole is a dopamine agonist weeks – Significant affinity for D2 – Completion ACT 82% vs PBO 62% • Ki = 3.1 nM – Includes 1 drop out in active arm • Antagonism of D receptor is with disorganization 2 – 3 completers with new or crucial for antipsychotic worsening hallucinations at top efficacy dose – More affinity for D3 – PANSS-Pos • Ki = 0.23 nM • ACT -9.5 (48); PBO +20.9 (60)* • Proposed mechanism of P=.006 action for treating psychosis – PANSS-Neg • ACT -9.2 (28); PBO -15.7 (16) RLS = restless legs syndrome; SC = schizophrenia; SA = schizoaffective disorder; ACT = active; PBO = placebo; PANSS = Positive and Negative Syndrome Scale. Signorelli MS, et al. BMJ Case Rep. 2013;2013. Hollingworth SA, et al. Drugs Real World Outcomes. 2015;2(3):199-203. Sautel F, et al. Neuroreport. 1995;6(2):329-332. Wang S, et al. Nature. 2018;555(7695):269-273. Kelleher JP, et al. Eur Neuropsychopharmacol. 2012;22(6):415-418. Ranking the Prevalence of Interactions that Limit Efficacy • Electronic Chart Review – Genoa Healthcare Database • Largest provider of pharmacy services to behavioral health and addiction treatment communities – Multiple Community Mental Health organizations • All records between January 1, 2016 and May 20, 2018 – Inclusion based on concurrence of 3 types of evidence • Indications and side effects • Mechanism of action • Clinical studies of combination Zarkowski P. 2018; In preparation. #70 Fluoxetine and Cyproheptadine #70 Fluoxetine & Cyproheptadine #71 Sertraline & Cyproheptadine #70 Paroxetine & Cyproheptadine Opposing Clinical Actions and Side Effects Fluoxetine Cyproheptadine FDA indication for Off-label treatment for Major Depression Anorgasmia due to SSRIs Sexual Dysfunction in 36% of Case series of depressive patients on Fluoxetine relapse SSRI = selective serotonin reuptake inhibitor. Benazzi F, et al. Pharmacopsychiatry. 1994;27(6):246. Lauerma H. Acta Psychiatr Scand. 1996;93(1):69-70. Feder R. J Clin Psychiatry. 1991;52(4):163-164. Goldbloom DS, et al. J Clin Psychiatry. 1991;52(6):261-262. Christensen RC. J Clin Psychiatry. 1995;56(9):433-434. Conflicting Mechanism of Action Equilibrium Constant 5-HT1A Serotonin Receptor Ki (nM) Cyproheptadine Fluoxetine • Fluoxetine inhibits the reuptake of H1 0.5 6200 serotonin 5-HT1A 69 > 10,000 • Cyproheptadine is an antagonist at 5-HT 5-HT2A 6.1 196 1A • 5-HT and antidepressant efficacy 5-HT2C 2.2 181 1A SERT - 16 – Shown to be crucial for efficacy in forced swim protocol in rats – Suggested intermediate role in the MOA of antidepressants – Relevance of receptor highlighted by vilazodone and vortioxetine MOA = mechanism of action; SERT = serotonin transporter. Psychoactive Drug Screening Program (PDSP). https://pdsp.unc.edu/databases/pdsp.php. Accessed April 14, 2018. Redrobe JP, et al. Eur J Pharmacol. 1996;318(2-3):213-220. Schreiber S, et al. J Mol Neurosci. 2002;18(1-2):143-149. Navinés R, et al. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(8):1804-1809. Kirilly E, et al. Neuropsychopharmacol Hung. 2015;17(2):81-89. Clinical Interaction Supported by Case Studies • Reversal of antidepressant activity of fluoxetine by cyproheptadine – Case study of 3 males treated for anorgasmia • Loss of response of fluoxetine after addition of cyproheptadine – Case study of 2 patients taking fluoxetine for bulimia nervosa • Interaction not limited to fluoxetine – Case study of cyproheptadine reversing antidepressant effect of paroxetine Feder R. J Clin Psychiatry. 1991;52(4):163-164. Goldbloom DS, et al. J Clin Psychiatry. 1991;52(6):261-262. Christensen RC. J Clin Psychiatry. 1995;56(9):433-434. Suggestions to Try Instead • Dose reduction of fluoxetine • Switch to antidepressant with less sexual side effects – Mirtazapine • 5-HT2A antagonist – Bupropion • No serotonergic activity • Add trazodone to existing SSRI – Open-label study showed improvement in 4 dimensions of sexual function • Possible role of 5-HT2A Benazzi F, et al. Pharmacopsychiatry. 1994;27(6):246. Clayton AH, et al. Postgrad Med. 2014;126(2):91-99. Stryjer R, et al. Clin Neuropharmacol. 2009;32(2):82-84. #57 Amitriptyline and Naltrexone #57 Amitriptyline & Naltrexone #73 Nortriptyline & Naltrexone Clinical Actions Naltrexone Amitriptyline FDA indication for FDA indication for Alcohol and Opioid Use Depression Disorder Off-label use for Pain Rascol O, et al. Clin Neuropharmacol. 1987;10(6):560-564. Mechanism of Action Equilibrium Constant Interaction via Opioid Receptors Ki (nM) Naltrexone Naloxone Amitriptyline • Naltrexone is a long-acting opioid Opioid- 26 52 - blocker, similar to naloxone δ • Amitriptyline inhibits the reuptake Opioid- 1.75 30 - of serotonin and norepinephrine κ • 10 days of amitriptyline blocks Opioid- 0.39 3.7 - mechanically-induced allodynia μ from sciatic nerve cuffing in rats SERT - 39 – No effect from sertraline NET - 68 – Effect reversed by naloxone • μ and κ receptor knock out mice have localized MOA of TCAs to δ NET = norepinephrine transporter; TCA = tricyclic antidepressant. receptors Psychoactive Drug Screening Program (PDSP). https://pdsp.unc.edu/databases/pdsp.php. Accessed April 14, 2018. Benbouzid M, et al. Eur J Pain. 2008;12(8):1008-1017. Bohren Y, et al. Eur J Pain. 2010;14(7):700-704. Megat S, et al. Br J Pharmacol. 2015;172(4):1034-1044. Norepinephrine is the Missing Link • 21 days of nortriptyline blocked mechanically-induced allodynia from sciatic nerve cuffing in rats – Effect was blocked by propranolol • β(2)-AR antagonist ICI 118,551 – Not affected by • Yohimbine, α(2)-AR antagonist • Metoprolol or atenolol • β(3)-AR antagonist SR 59230A – Effect of nortriptyline was also totally absent in β(2)-AR-deficient mice AR = adrenergic receptor. Yalcin I, et al. Ann Neurol. 2009;65(2):218-225. Interaction Verified in Additional Pain Protocol • Acetic acid-induced abdominal constriction assay in mice – Naloxone shifts the dose-response curve of amitriptyline to the right • Studies on interaction in humans are scarce – In one case study 3 challenges of naltrexone caused depressive relapse 3 separate times in a patient that had responded to amitriptyline **P<.01 vs amitriptyline and vehicle regression line. Gray AM, et al. Br J Pharmacol. 1998;124(4):669-674. Schürks M, et al. Pharmacopsychiatry. 2005;38(2):100-102. Not All Pain Medications are Blocked by Naltrexone • NSAIDs – Naloxone had no effect on the dose-response curve of ASA in mice – Pretreatment with naltrexone blocked the analgesic response of codeine but not IBU in patients undergoing dental surgery • AEDs – Naltrexone blocked the antinociceptive properties of morphine but not gabapentin in mice injected with HSV-1 – Replicated in sciatic nerve cuffing NSAID = nonsteroidal anti-inflammatory drug; ASA = aspirin; IBU = ibuprofen; AED = anti-epileptic drug; HSV-1 = herpes simplex virus type-1. Gray AM, et al. Br J Pharmacol. 1998;124(4):669-674. Hersh EV, et al. Oral Surg Oral Med Oral Pathol. 1993;75(5):539-546. Takasaki I, et al. J Pharmacol Exp Ther. 2001;296(2):270-275. Benbouzid M, et al. Eur J Pain. 2008;12(8):1008-1017. #38 Amphetamine-Dextroamphetamine and Haloperidol #12 Amphetamine-Dextroamphetamine & Aripiprazole; #15 Amphetamine- Dextroamphetamine & Quetiapine; #16 Amphetamine-Dextroamphetamine & Risperidone; #27 Amphetamine-Dextroamphetamine & Olanzapine; #31 Amphetamine-Dextroamphetamine & Lurasidone; #38 Amphetamine- Dextroamphetamine & Haloperidol; #39 Amphetamine-Dextroamphetamine & Paliperidone; #48 Amphetamine-Dextroamphetamine + Asenapine Opposing Clinical Actions and Side Effects Haloperidol Dextroamphetamine effective Tx for FDA indication for ADHD Amphetamine-Induced Psychosis Drug-Induced Psychosis in 8% to 46% of regular users Opposite Effect on Clock depending
Load more

Recommended publications
  • (12) United States Patent (10) Patent N0.: US 7,964,607 B2 Verhoest Et A1
    US007964607B2 (12) United States Patent (10) Patent N0.: US 7,964,607 B2 Verhoest et a1. (45) Date of Patent: Jun. 21, 2011 (54) PYRAZOLO[3,4-D]PYRIMIDINE FOREIGN PATENT DOCUMENTS COMPOUNDS EP 1460077 9/2004 WO 02085904 10/2002 (75) Inventors: Patrick Robert Verhoest, Old Lyme, CT WO 2004037176 5/2004 (US); Caroline ProulX-Lafrance, Ledyard, CT (US) OTHER PUBLICATIONS Wunder et a1, M01. PharmacoL, v01. 28, N0. 6, (2005), pp. 1776 (73) Assignee: P?zer Inc., New York, NY (U S) 1781. van der Staay et a1, Neuropharmacology, v01. 55 (2008), pp. 908 ( * ) Notice: Subject to any disclaimer, the term of this 918. patent is extended or adjusted under 35 USC 154(b) by 562 days. Primary Examiner * Susanna Moore (74) Attorney, Agent, or Firm * Jennifer A. Kispert; (21) Appl.No.: 12/118,062 Michael Herman (22) Filed: May 9, 2008 (57) ABSTRACT (65) Prior Publication Data The invention provides PDE9-inhibiting compounds of For US 2009/0030003 A1 Jan. 29, 2009 mula (I), Related US. Application Data (60) Provisional application No. 60/917,333, ?led on May 11, 2007. (51) Int. Cl. C07D 48 7/04 (2006.01) A61K 31/519 (2006.01) A61P 25/28 (2006.01) (52) US. Cl. ................................... .. 514/262.1; 544/262 (58) Field of Classi?cation Search ................ .. 544/262; 5 1 4/2 62 .1 See application ?le for complete search history. and pharmaceutically acceptable salts thereof, Wherein R, R1, (56) References Cited R2 and R3 are as de?ned herein. Pharmaceutical compositions containing the compounds of Formula I, and uses thereof in U.S.
    [Show full text]
  • PR2'2006.Vp:Corelventura
    Modulation of chemical signalling: Current problems after four decades of research Symposium 5-HT3 receptors and emesis Martin Barann1,2, Michael Bruess2, Marion Brinkmann1, Isabelle Linden1, Mina Lyutenska1, Marc Schneider1, Jan Walkembach1, Maria Wittmann1 Clinics of Anaesthesiology and Operative Intensive Care, University of Bonn, Sigmund-Freud-Str. 25, D-53105 Bonn, Germany; Institute of Pharmacology and Toxicology, University of Bonn, Reuterstr. 2b, D-53113 Bonn, Germany; e-mail: [email protected] Nausea and vomiting. Nausea and vomiting is a ma- mechanisms. In recent studies, the molecular mecha- jor problem which occurs during and after the treat- nisms of (anti)emetic drugs at this receptor have been ment with certain drugs like anesthetics, opioid- studied [Barann, et al., Naunyn Schmiedebergs Arch analgesics or cytostatics. Postoperative nausea and Pharmacol, 2000; Barann et al., Neuropharmacology, vomiting (PONV) is called the “big” little problem. 2000; Barann et al., Br J Pharmacol, 2002; Walkem- As a consequence, the choice of the anesthetic drug(s) bach et al., Br J Pharmacol, 2005; Barann et al., Eur J plays a role in preventing PONV [Apfel et al., Anes- Pharamacol, 2006]. For this purpose, excised thesiology, 1999; Eberhart et al., Eur J Anaesthesiol, outside-out patches of HEK293 cells, stably trans- via 1999]. Nausea and vomiting can be mediated pe- fected with the human 5-HT3A receptor cDNA were ripheral and/or central nervous pathways. Within the formed (voltage-clamp mode) and fast solution exchange peripheral nervous system, vagal afferents, which are systems were used. In addition, radioligand binding stud- stimulated by 5-HT released from enterochromaffin ies and [3H]5-HT uptake measurements (study of the cells, are of importance.
    [Show full text]
  • Biol. Pharm. Bull. 42(5): 736-743 (2019)
    736 Biol. Pharm. Bull. 42, 736–743 (2019) Vol. 42, No. 5 Regular Article Noradrenaline-Induced Relaxation of Urinary Bladder Smooth Muscle Is Primarily Triggered through the β3-Adrenoceptor in Rats Keisuke Obara,a Serena Suzuki,a Hiroko Shibata,a Naoki Yoneyama, a Shoko Hamamatsu,a Fumiko Yamaki,a Koji Higai,b and Yoshio Tanaka*,a a Department of Chemical Pharmacology, Faculty of Pharmaceutical Sciences, Toho University; 2–2–1 Miyama, Funabashi, Chiba 274–8510, Japan: and b Laboratory of Medical Biochemistry, Faculty of Pharmaceutical Sciences, Toho University; 2–2–1 Miyama, Funabashi, Chiba 274–8510, Japan. Received November 18, 2018; accepted January 25, 2019 β-Adrenoceptors are subclassified into 3 subtypes (β1–β3). Among these, β3-adrenoceptors are present in various types of smooth muscle and are believed to play a role in relaxation responses of these muscles. β3-Adrenoceptors are also present in urinary bladder smooth muscle (UBSM), although their expression varies depending on the animal species. To date, there has been little information available about the endo- genous ligand that stimulates β3-adrenoceptors to produce relaxation responses in UBSM. In this study, to determine whether noradrenaline is a ligand of UBSM β3-adrenoceptors, noradrenaline-induced relaxation was analyzed pharmacologically using rat UBSM. We also assessed whether noradrenaline metabolites were ligands in UBSM. In isolated rat urinary bladder tissues, mRNAs for β1-, β2-, and β3-adrenoceptors were detected using RT-PCR. In UBSM preparations contracted with methacholine (3 105 M), noradrenaline- 6 induced relaxation was not inhibited by the following antagonists: atenolol (10 M; selective β1-adrenoceptor 8 7 antagonist), ICI-118,551 (3 10 M; selective β2-adrenoceptor antagonist), propranolol (10 M; non-selective β-adrenoceptor antagonist), and bupranolol (107 M; non-selective β-adrenoceptor antagonist).
    [Show full text]
  • Sympathoadrenergic Modulation of Hematopoiesis: a Review of Available Evidence and of Therapeutic Perspectives
    REVIEW published: 05 August 2015 doi: 10.3389/fncel.2015.00302 Sympathoadrenergic modulation of hematopoiesis: a review of available evidence and of therapeutic perspectives Marco Cosentino*, Franca Marino and Georges J. M. Maestroni Center for Research in Medical Pharmacology, University of Insubria, Varese, Italy Innervation of the bone marrow (BM) has been described more than one century ago, however the first in vivo evidence that sympathoadrenergic fibers have a role in hematopoiesis dates back to less than 25 years ago. Evidence has since increased showing that adrenergic nerves in the BM release noradrenaline and possibly also dopamine, which act on adrenoceptors and dopaminergic receptors (DR) expressed on hematopoietic cells and affect cell survival, proliferation, migration and engraftment ability. Remarkably, dysregulation of adrenergic fibers to the BM is associated with hematopoietic disturbances and myeloproliferative disease. Several adrenergic and dopaminergic agents are already in clinical use for non-hematological indications and with a usually favorable risk-benefit profile, and are therefore potential candidates for Edited by: non-conventional modulation of hematopoiesis. Wanda Lattanzi, Università Cattolica del Sacro Cuore, Keywords: dopamine, noradrenaline, adrenaline, adrenoceptors, dopaminergic receptors, hematopoiesis, Italy neuroimmune phamacology, drug repurposing Reviewed by: Sujit Basu, Introduction Ohio State University, USA Tsvee Lapidot, Weizmann Institute of Science, Israel The term ‘‘niche’’, derived from the Latin word ‘‘mytilus’’ (mussel), has eventually come to designate a shallow recess in a wall, as for a statue or other decorative object, in view of the *Correspondence: similarity with the shape of a seashell, and broadly a place suitable or appropriate for a person or Marco Cosentino, Center for Research in Medical thing.
    [Show full text]
  • Neurotransmission Product Guide | Edition 1
    Neurotransmission Product Guide | Edition 1 Delphinium Delphinium A source of Methyllycaconitine Contents by Research Area: • Dopaminergic Transmission • Glutamatergic Transmission • Opioid Peptide Transmission • Serotonergic Transmission • Chemogenetics Tocris Product Guide Series Neurotransmission Research Contents Page Principles of Neurotransmission 3 Dopaminergic Transmission 5 Glutamatergic Transmission 6 Opioid Peptide Transmission 8 Serotonergic Transmission 10 Chemogenetics in Neurotransmission Research 12 Depression 14 Addiction 18 Epilepsy 20 List of Acronyms 22 Neurotransmission Research Products 23 Featured Publications and Further Reading 34 Introduction Neurotransmission, or synaptic transmission, refers to the passage of signals from one neuron to another, allowing the spread of information via the propagation of action potentials. This process is the basis of communication between neurons within, and between, the peripheral and central nervous systems, and is vital for memory and cognition, muscle contraction and co-ordination of organ function. The following guide outlines the principles of dopaminergic, opioid, glutamatergic and serotonergic transmission, as well as providing a brief outline of how neurotransmission can be investigated in a range of neurological disorders. Included in this guide are key products for the study of neurotransmission, targeting different neurotransmitter systems. The use of small molecules to interrogate neuronal circuits has led to a better understanding of the under- lying mechanisms of disease states associated with neurotransmission, and has highlighted new avenues for treat- ment. Tocris provides an innovative range of high performance life science reagents for use in neurotransmission research, equipping researchers with the latest tools to investigate neuronal network signaling in health and disease. A selection of relevant products can be found on pages 23-33.
    [Show full text]
  • (C) Hit Agreement Between Seeding Densities
    (a) Morphological space (b) Identification of hits (c) Hit agreement between 1500 cells per well 1500 cells per well seeding densities DMSO 8 1.00 Pentamidine 1.00 Wiskostatin Hydroxychloroquine Imatinib 0.75 0.75 4 Gefitinib Compound DMSO Pentamidine 0.50 0.50 0 Vinblastine UMAP2 Wiskostatin Vinblastine 0.25 0.25 Vinblastine −4 Plate at 1500 cells/well Robust Hellinger Distance Wiskostatin Pentamidine 0.00 DMSO 0.00 −4 0 4 0.00 0.25 0.50 0.75 1.00 0.00 0.25 0.50 0.75 1.00 UMAP1 FDR−corrected p−value Plate at 750 cells/well Supp. Figure 1: BioProfiling.jl profiles of plates seeded at 750 and 1500 cells per well curated with are similar. (a) UMAP embedding preserving the cosine distance between the mor-phological profiles aggregated per field of view in the plate seeded with 1500 cells per well. Two out of four dimensions are represented. (b) Robust Hellinger distance and Ro-bust Morphological Perturbation Value (FDR-corrected p-value) of each compound in the plate seeded with 1500 cells per well compared to DMSO. Vertical dotted line indicates an FDR threshold of 0.1 and all compounds on its left are defined as morphological hits. (c) FDR-corrected p-value of the significance of morphological changes induced by each compound in both plates. Dotted lines indicate an FDR threshold of 0.1. CompoundName MOA Targets RMPV750 RMPV1500 (+)-Butaclamol hydrochloride 0.2479179 0 (+)-Cyclazocine 0.0288018 0.0012478 ["ABCC1", "ABCC2", "FPR1", (+/-)-Sulfinpyrazone ["Uricosuric blocker"] "SLC22A12"] 0.0019172 0.015413 (-)-JQ1 0.0003682 0 (-)-Perillic
    [Show full text]
  • Proteostasis of Glial Intermediate Filaments: Disease Models, Tools, and Mechanisms
    PROTEOSTASIS OF GLIAL INTERMEDIATE FILAMENTS: DISEASE MODELS, TOOLS, AND MECHANISMS Rachel Anne Battaglia A dissertation submitted to the faculty at the University of North Carolina at Chapel Hill in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Department of Cell Biology and Physiology in the School of Medicine. Chapel Hill 2021 Approved by: Natasha T. Snider Carol Otey Keith Burridge Douglas Cyr Mohanish Deshmukh Damaris Lorenzo i © 2021 Rachel Anne Battaglia ALL RIGHTS RESERVED ii ABSTRACT Rachel Anne Battaglia: Proteostasis of Glial Intermediate Filaments: Disease Models, Tools, and Mechanisms (Under the direction of Natasha T. Snider) Astrocytes are a major glial cell type that is crucial for the health and maintenance of the Central Nervous System (CNS). They fulfill diverse functions, including synapse formation, neurogenesis, ion homeostasis, and blood brain barrier formation. Intermediate filaments (IFs) are components of the astrocyte cytoskeleton that support many of these functions in healthy individuals. However, upon cellular stress or genetic mutations, IF proteins are prone to accumulation and aggregation. These processes are thought to contribute to disease pathogenesis of different tissue-specific disorders, but therapeutic targeting of IFs is hindered by a lack of pharmacological tools to modulate their assembly and disassembly states. Moreover, the mechanisms that govern the formation and dissolution of IF aggregates are poorly defined. In this dissertation, I investigate IF aggregates called Rosenthal fibers (RFs), which form in astrocytes of patients with two pediatric neurodegenerative diseases, Alexander disease (AxD) and Giant Axonal Neuropathy (GAN). My aim was to gain a better understanding of the mechanisms of how astrocyte IF protein aggregates form and interrogate the role of post- translational modifications (PTMs) in this process.
    [Show full text]
  • ( 12 ) United States Patent
    US010493080B2 (12 ) United States Patent (10 ) Patent No.: US 10,493,080 B2 Schultz et al. (45 ) Date of Patent : Dec. 3 , 2019 ( 54 ) DIRECTED DIFFERENTIATION OF (56 ) References Cited OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE U.S. PATENT DOCUMENTS 7,301,071 B2 11/2007 Zheng (71 ) Applicants : The Scripps Research Institute , La 7,304,071 B2 12/2007 Cochran et al. Jolla , CA (US ) ; Novartis AG , Basel 9,592,288 B2 3/2017 Schultz et al. 2003/0225072 A1 12/2003 Welsh et al. ( CH ) 2006/0258735 Al 11/2006 Meng et al. 2009/0155207 Al 6/2009 Hariri et al . (72 ) Inventors : Peter Schultz , La Jolla , CA (US ) ; Luke 2010/0189698 A1 7/2010 Willis Lairson , San Diego , CA (US ) ; Vishal 2012/0264719 Al 10/2012 Boulton Deshmukh , La Jolla , CA (US ) ; Costas 2016/0166687 Al 6/2016 Schultz et al. Lyssiotis , Boston , MA (US ) FOREIGN PATENT DOCUMENTS (73 ) Assignees : The Scripps Research Institute , La JP 10-218867 8/1998 Jolla , CA (US ) ; Novartis AG , Basel JP 2008-518896 5/2008 (CH ) JP 2010-533656 A 10/2010 WO 2008/143913 A1 11/2008 WO 2009/068668 Al 6/2009 ( * ) Notice : Subject to any disclaimer , the term of this WO 2009/153291 A1 12/2009 patent is extended or adjusted under 35 WO 2010/075239 Al 7/2010 U.S.C. 154 ( b ) by 0 days . (21 ) Appl. No .: 15 /418,572 OTHER PUBLICATIONS Molin - Holgado et al . “ Regulation of muscarinic receptor function in ( 22 ) Filed : Jan. 27 , 2017 developing oligodendrocytes by agonist exposure ” British Journal of Pharmacology, 2003 , 138 , pp .
    [Show full text]
  • Involvement of Я3-Adrenergic Receptor Activation Via Cyclic
    Involvement of ␤3-adrenergic receptor activation via cyclic GMP- but not NO-dependent mechanisms in human corpus cavernosum function Giuseppe Cirino*†, Raffaella Sorrentino*†, Roberta d’Emmanuele di Villa Bianca*, Ada Popolo‡, Alessandro Palmieri§, Ciro Imbimbo§, Ferdinando Fusco§, Nicola Longo§, Gianfranco Tajana‡, Louis J. Ignarro¶ʈ, and Vincenzo Mirone§ Dipartimentos di *Farmacologia Sperimentale e §Urologia, Facolta`di Medicina Universita`di Napoli-Federico II, 80131 Naples, Italy; ‡Dipartimento di Scienze Farmaceutiche, Universita`di Salerno, 84100 Fisciano-Salerno, Italy; and ¶Department of Molecular and Medical Pharmacology, University of California School of Medicine, Los Angeles, CA 90095-1735 Contributed by Louis J. Ignarro, March 7, 2003 ␤ ␤ The 3-adrenoreceptor plays a major role in lipolysis but the role and possess 3-receptors that share most of the characteristic prop- distribution of ␤3-receptors in other specific sites have not been erties, although some species-specific differences have been ␤ ␤ extensively studied. 3-adrenergic receptors are present not only in identified. The 3-receptor plays a major role in lipolysis but the ␤ adipose tissue but also in human gall bladder, colon, prostate, and role and distribution of 3-receptors in other specific sites have skeletal muscle. Recently, ␤3-adrenergic receptor stimulation was not been extensively studied. Tissue distribution studies have ␤ shown to elicit vasorelaxation of rat aorta through the NO–cGMP demonstrated the presence of 3-receptors not only in adipose signal transduction pathway. Here we show that ␤3-receptors are tissues but also in human gall bladder and more recently in colon, ␤ present in human corpus cavernosum and are localized mainly in prostate, and skeletal muscle (9–11).
    [Show full text]
  • The Full Expression of Fasting-Induced Torpor Requires ␤3-Adrenergic Receptor Signaling
    The Journal of Neuroscience, January 4, 2006 • 26(1):241–245 • 241 Brief Communication The Full Expression of Fasting-Induced Torpor Requires ␤3-Adrenergic Receptor Signaling Steven J. Swoap,1 Margaret J. Gutilla,1 L. Cameron Liles,2 Ross O. Smith,1 and David Weinshenker2 1Department of Biology, Williams College, Williamstown, Massachusetts 01267 and 2Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia 30322 Torpor, a controlled rapid drop in metabolic rate and body temperature (Tb ), is a hypometabolic adaptation to stressful environmental conditions, which occurs in many small mammals, marsupials, and birds. To date, signaling pathways required for torpor have not been identified. We examined the role of the sympathetic nervous system (SNS) in mediating the torpor adaptation to fasting by telemetrically ؊ ؊ ␤ monitoring the Tb of dopamine -hydroxylase knock-out (Dbh / ) mice, which lack the ability to produce the SNS transmitters, norepinephrine (NE), and epinephrine. Control (Dbh؉/؊) mice readily reduced serum leptin levels and entered torpor after a fast in a -cool environment. In contrast, Dbh؊/؊ mice failed to reduce serum leptin and enter torpor under fasting conditions, whereas restora tion of peripheral but not central NE lowered serum leptin levels and rescued the torpor response. Torpor was expressed in fasted Dbh؊/؊ mice immediately after administration of either the nonselective ␤-adrenergic receptor agonist isoproterenol or the ␤3- adrenergic receptor (AR)-specific agonist CL 316243 [disodium (RR)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]-amino]propyl]-1,3- benzodioxazole-2,2-dicarboxylate], but not after administration of ␤1, ␤2, or ␣1 agonists. Importantly, the ␤3-specific antagonist SR 59230A [3-(2-ethylphenoxy)-1-[(1,S)-1,2,3,4-tetrahydronapth-1-ylamino]-2S-2-propanol oxalate] severely blunted fasting-induced tor- por in control mice, whereas other AR antagonists were ineffective.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0076019 A1 Tyers Et Al
    US 20090076019A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0076019 A1 Tyers et al. (43) Pub. Date: Mar. 19, 2009 (54) METHODS FOR TREATING Publication Classification NEUROLOGICAL DISORDERS OR DAMAGE (51) Int. Cl. Inventors: Mike Tyers, Toronto (CA); Phedias A63/496 (2006.01) (75) CI2O 1/02 (2006.01) Diamandis, Toronto (CA); Peter B. A6II 3/445 (2006.01) Dirks, Toronto (CA) A63/64 (2006.01) Correspondence Address: A6IP 25/00 (2006.01) HOWSON AND HOWSON A6IP 25/6 (2006.01) SUITE 210,501 OFFICE CENTER DRIVE A6IP 25/18 (2006.01) FT WASHINGTON, PA 19034 (US) (52) U.S. Cl. ...................... 514/252.13:435/29: 514/317; 514f613 (73) Assignees: Mount Sinai Hospital, Toronto (CA); HSC Research and Development Limited (57) ABSTRACT Partnership, Toronto (CA) A clonogenic neurosphere assay is described that carries out high throughput screens (HTS) to identify potent and/or (21) Appl. No.: 11/871,562 selective modulators of proliferation, differentiation and/or renewal of neural precursor cells, neural progenitor cells and/ (22) Filed: Oct. 12, 2007 or self-renewing and multipotent neural stem cells (NSCs). Compositions comprising the identified modulators and Related U.S. Application Data methods of using the modulators and compositions, in par (60) Provisional application No. 60/851,615, filed on Oct. ticular to treat neurological disorders (e.g. brain or CNS can 13, 2006. cer) or damage are also disclosed. Neurosphere Stein Progenitor Differentiated eEE eEE t Prolifefatic Assay Patent Application Publication Mar. 19, 2009 Sheet 1 of 26 US 2009/0076019 A1 Figure 1 Neurosphere Progenitor O Defeitiated e CE M.
    [Show full text]
  • Tocris製品30％Offキャンペーン価格表（2021/7/5～2021/8/31）
    TOCRIS製品30％OFFキャンペーン価格表（2021/7/5～2021/8/31） （メーカーコード順） 希望納⼊価格 キャンペーン価格 コードNo.メーカーコード 英名 容量 (円） (円） 537-31171 0101/100 DL-2-Amino-4-phosphonobutyric Acid [DL-AP4] 100mg 24,000 16,800 - 0102/10 D(-)-2-Amino-4-phosphonobutyric Acid [D-AP4] 10mg 52,000 36,400 - 0102/50 D(-)-2-Amino-4-phosphonobutyric Acid [D-AP4] 50mg 222,000 155,400 - 0103/1 L(+)-2-Amino-4-phosphonobutyric Acid [L-AP4] 1mg 18,000 12,600 531-26804 0103/10 L(+)-2-Amino-4-phosphonobutyric Acid [L-AP4] 10mg 46,000 32,200 533-26803 0103/50 L(+)-2-Amino-4-phosphonobutyric Acid [L-AP4] 50mg 203,000 142,100 - 0104/10 DL-AP7 10mg 30,000 21,000 - 0104/50 DL-AP7 50mg 120,000 84,000 - 0105/10 DL-AP5 10mg 20,000 14,000 530-57943 0105/50 DL-AP5 50mg 81,000 56,700 - 0106/1 D-AP5 1mg 15,000 10,500 531-26843 0106/10 D-AP5 10mg 39,000 27,300 535-26846 0106/100 D-AP5 100mg 235,000 164,500 539-26844 0106/50 D-AP5 50mg 174,000 121,800 - 0107/10 L-AP5 10mg 54,000 37,800 - 0107/50 L-AP5 50mg 235,000 164,500 514-20993 0109/10 (-)-Bicuculline methobromide 10mg 28,000 19,600 518-20991 0109/50 (-)-Bicuculline methobromide 50mg 126,000 88,200 - 0111/1 Dihydrokainic acid 1mg 17,000 11,900 - 0111/10 Dihydrokainic acid 10mg 42,000 29,400 - 0111/50 Dihydrokainic acid 50mg 189,000 132,300 532-28291 0112/50 gamma-D-Glutamylglycine 50mg 38,000 26,600 539-26861 0114/50 N-Methyl-D-aspartic Acid [NMDA] 50mg 24,000 16,800 535-26863 0114/500 N-Methyl-D-aspartic Acid [NMDA] 500mg 100,000 70,000 533-31151 0125/100 DL-AP3 100mg 30,000 21,000 512-21011 0130/50 (+)-Bicuculline 50mg 47,000 32,900 535-57954 0131/10 (-)-Bicuculline
    [Show full text]